Dr. Carmen Diez joined NUVISAN in June 2021 as Senior Director Business Development, responsible for working with Venture Capital worldwide. She is a biomedical scientist by training, with a PhD and Postdoc in the field of metabolic rare disorders. Since 2017, she worked for several healthcare Venture Capitals and held positions as Secretary of the Investment Committee and Board Observer at a US-based biotech.
Arnoud joined NUVISAN in August 2020 as Managing Director & Chief Strategy Officer right after the Innovation Campus Berlin acquisition. He has over 25 years of experience in leadership positions in Life Sciences, like Pharma, CRO, M&A, medical devices, start-ups and Venture Capital. Entrepreneur who firmly believes in the power of collaboration and innovation as ways to marriage Science and Value.
Dr. Charlotte Kopitz is Biologist by training with a passion for applied research. She started academic research in the field of natural pest control/Zoology, followed by basic research on the autoimmune disease sprue, followed by a PhD as well as Postdoc in the field of Experimental Oncology. In 2008 she took over the lead of an in vivo Laboratory in Oncology Research at Bayer, with increasing repertoire and responsibilities, incl. project leadership along the value chain, membership of the Global Bayer Animal Welfare Committee and Inclusion and the role as Inclusion & Diversity Advisor of the Bayer Pharma R&D organization. In 2019 she took over the responsibility for Pharmacology of the Innovation Campus Berlin at Bayer, preparing the transition to NUVISAN GmbH. At July 1st 2020 she became EVP and Head of Therapeutic Research in the Innovation Campus Berlin as part of the NUVISAN family.
